novartis q4 - Search News

Novartis beats Q4 earnings consensus

The Motley Fool on MSN · 45m

Novartis Ag (NVS) Q4 2024 Earnings Call Transcript

Good morning and good afternoon, and welcome to the Novartis Q4 2024 results release conference call and live webcast. [Operator instructions] The conf

Novartis beats Q4 earnings consensus as drug sales surge

Novartis on Friday posted adjusted net income well above analyst estimates as sales of established heart failure drug Entresto and newer multiple sclerosis drug Kesimpta exceeded forecasts.

Novartis Eyes More Bolt-On Deals in 2025 as Q4 Earnings Easily Beat Consensus

Novartis was among the most prolific pharma dealmakers in 2024, a trend that it expects to continue with more bolt-on deals this year to set up for sustainable long-term growth.

7h

Novartis Q4 Earnings: Revenue And EPS Beat, CEO Dismisses Entresto Patent Expiration Worries

Novartis AG (NYSE:NVS) shares are trading higher in the premarket session on Friday. The Swiss pharma giant reported ...

6h

Balanced Caution: Novartis’s Strong Q4 Performance Amidst Growth Uncertainties

J.P. Morgan analyst Richard Vosser has maintained their neutral stance on NOVN stock, giving a Hold rating today.Invest with Confidence: ...

3hon MSN

Novartis has cash for a big pharma deal—but here’s why it’s not buying

Novartis chief executive says large pharma deals usually don't pay off. But the company remains interested in bolt-on ...

2hon MSN

Novartis delays Phase 3 readout for Ionis heart drug

Ionis Pharmaceuticals (IONS) stock slips as Novartis (NVS) delays Phase 3 trial data for its cardiac therapy pelacarsen. Read more here.

5h

Novartis Q4 Core EPS Beats Market, Hikes Dividend; Sees Growth In FY25; Stock Up

Swiss drug-major Novartis AG reported Friday weak net earnings in its fourth quarter on the absence of prior year's significant gain ...

Some results have been hidden because they may be inaccessible to you

Show inaccessible results